ADMA · Adma Biologics Inc
United States · RS rating 64 · As of 2026-10-14
| Price | 10.34 USD |
|---|---|
| 1-day change | +0.3% |
| RS rating (overall / 1M / 3M / 12M) | 64 / 97 / 90 / 22 |
| Stage | Declining |
| Composite / Minervini / CANSLIM score | 27 / 24 / 24 |
| Industry group (rank) | Medical-Biomed/Biotech (167) |
| EPS growth Q/Q | +33.3% |
| Sales growth Q/Q | +3.7% |
| Distance from 52-week high | +49.3% |
| Market cap (USD) | $2.6B |